Roche Holding AG (RHHVF)
OTCMKTS
· Delayed Price · Currency is USD
280.00
+4.77 (1.73%)
Dec 24, 2024, 10:35 AM EST
Roche Holding AG Employees
Roche Holding AG had 103,605 employees as of December 31, 2023. The number of employees decreased by 8 or -0.01% compared to the previous year.
Employees
103,605
Change (1Y)
-8
Growth (1Y)
-0.01%
Revenue / Employee
$650,713
Profits / Employee
$114,061
Market Cap
223.87B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 103,605 | -8 | -0.01% |
Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
Dec 31, 2021 | 100,920 | -545 | -0.54% |
Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
Dec 31, 2019 | 97,735 | 3,293 | 3.49% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Sandoz Group AG | 22,633 |
Telix Pharmaceuticals Limited | 234 |
Elekta AB (publ) | 4,718 |
Ryman Healthcare Limited | 7,700 |
Verano Holdings Corp. | 3,900 |
Vireo Growth Inc. | 490 |
Medexus Pharmaceuticals Inc. | 82 |
Roche Holding AG News
- 1 day ago - Experts gather in Hong Kong to tackle liver cancer together - South China Morning Post
- 5 days ago - Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits - Benzinga
- 5 days ago - Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study - The Wall Street Journal
- 5 days ago - Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study - WSJ
- 5 days ago - Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug - Seeking Alpha
- 5 days ago - Roche Halts Development of SPK-8011 Amid Strategic Gene Therapy Focus - GuruFocus
- 5 days ago - Roche's Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson's disease - GlobeNewsWire
- 5 days ago - Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease - Business Wire